PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity

PI3K inhibitors with differential selectivity to distinct PI3K isoforms have been tested extensively in clinical trials, largely to target tumor epithelial cells. PI3K signaling also regulates the immune system and inhibition of PI3Kδ modulate the tumor immune microenvironment of pre-clinical mouse...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Carnevalli, Larissa S., Sinclair, Charles, Taylor, Molly A., Gutierrez, Pablo Morentin, Langdon, Sophie, Coenen-Stass, Anna M. L., Mooney, Lorraine, Hughes, Adina, Jarvis, Laura, Staniszewska, Anna, Crafter, Claire, Sidders, Ben, Hardaker, Elizabeth, Hudson, Kevin, Barry, Simon T.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6307194/
https://ncbi.nlm.nih.gov/pubmed/30587236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0457-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares